350
Participants
Start Date
January 1, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
June 30, 2027
next generation sequencing AND Immunohistochemical examination
First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou
Fujian Provincial Hospital
OTHER
First Affiliated Hospital of Fujian Medical University
OTHER
Gutian Hospital
UNKNOWN
Fujian Cancer Hospital
OTHER_GOV